Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRM | P19623 | 3/20 | 0.59 |
| ▸ | SMS | P52788 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.58 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.58 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.58 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.58 |
| ▸ | LDHA | P00338 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.58 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418087 | 0.95 | SRM (0.57) | SRMSMSP2RY2P2RY1SRC | |
| SCHEMBL230821 | 0.91 | EHMT1 (0.63) | P2RY2P2RY1SRCSMN1; SMN2DNPH1 | |
| SCHEMBL30211841 | 0.90 | P2RY2 (0.59) | P2RY2P2RY1SRCSMN1; SMN2DNPH1 | |
| SCHEMBL29126399 | 0.90 | P2RY2 (0.59) | P2RY2P2RY1SRCSMN1; SMN2DNPH1 | |
| SCHEMBL8385440 | 0.89 | SRM (0.62) | SRMSMSSMN1; SMN2ADORA1NNMT | |
| Hydrochloric Acid SCHEMBL30211837 | 0.89 | P2RY2 (0.58) | P2RY2P2RY1SRCSMN1; SMN2DNPH1 | |
| Hydrochloric Acid SCHEMBL29126408 | 0.89 | P2RY2 (0.58) | P2RY2P2RY1SRCSMN1; SMN2DNPH1 | |
| SCHEMBL6826790 | 0.84 | SRM (0.59) | SRMSMSSMN1; SMN2ADORA1 | |
| SCHEMBL8440946 | 0.84 | P2RY2 (0.60) | P2RY2P2RY1SRCSMN1; SMN2P2RX1 | |
| SCHEMBL756245 | 0.83 | P2RY2 (0.64) | P2RY2P2RY1SRCSMN1; SMN2DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090175981-A1 | COMPOSITIONS, METHODS AND USES FOR A NOVEL FAMILY OF PEPTIDES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2009-07-09 | — | — | US | disclosed |
| US-7498404-B2 | Compositions, methods and uses for a novel family of peptides | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2009-03-03 | — | — | US | disclosed |
| US-7235651-B2 | Genes and proteins involved in the biosynthesis of lipopeptides | CUBIST PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060228398-A1 | Compositions, methods and uses for a novel family of peptides | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2006-10-12 | — | — | US | disclosed |
| US-20040033581-A1 | Dual condensation/epimerization domain in non-ribosomal peptide synthetase systems | ECOPIA BIOSCIENCES, INC. (CA) | 2004-02-19 | — | — | US | disclosed |
| US-20030211567-A1 | Compositions, methods and systems for discovery of lipopeptides | ECOPIA BIOSCIENCES, INC. | 2003-11-13 | — | — | US | disclosed |
| WO-2003089641-A2 | DUAL CONDENSATION/EPIMERIZATION DOMAIN IN NON-RIBOSOMAL PEPTIDE SYNTHETASE SYSTEMS | ECOPIA BIOSCIENCES INC. (CA) | 2003-10-30 | — | — | WO | disclosed |
| US-20030198981-A1 | Genes and proteins involved in the biosynthesis of lipopeptides | ECOPIA BIOSCIENCES, INC. | 2003-10-23 | — | — | US | disclosed |
| EP-0994943-A2 | METHOD OF ALTERING THE DOMAINS OF CYCLOSPORIN SYNTHETASE TO GIVE A MODIFIED CYCLOSPORIN SYNTHETASE | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999002659-A2 | METHOD OF ALTERING THE DOMAINS OF CYCLOSPORIN SYNTHETASE TO GIVE A MODIFIED CYCLOSPORIN SYNTHETASE | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1999-01-21 | — | — | WO | disclosed |